CY1121859T1 - Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης - Google Patents
Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδηςInfo
- Publication number
- CY1121859T1 CY1121859T1 CY20191100562T CY191100562T CY1121859T1 CY 1121859 T1 CY1121859 T1 CY 1121859T1 CY 20191100562 T CY20191100562 T CY 20191100562T CY 191100562 T CY191100562 T CY 191100562T CY 1121859 T1 CY1121859 T1 CY 1121859T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparation
- glycosyloceramide
- synthesis inhibitors
- treatment
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 abstract 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 230000002132 lysosomal effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Η εφεύρεση σχετίζεται με μία μέθοδο παρασκευής αναστολέων της συνθάσης γλυκοζυλοκεραμίδης (GCS) η οποία είναι χρήσιμη για τη θεραπευτική αντιμετώπιση μεταβολικών νόσων, όπως είναι τα λυσοσωμικά αθροιστικά νοσήματα, είτε μόνη της είτε σε συνδυασμό με θεραπεία ενζυμικής αντικατάστασης, καθώς και για τη θεραπευτική αντιμετώπιση του καρκίνου.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791913P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/025384 WO2014151291A1 (en) | 2013-03-15 | 2014-03-13 | Method of preparing glucosylceramide synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121859T1 true CY1121859T1 (el) | 2020-07-31 |
Family
ID=50543333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100562T CY1121859T1 (el) | 2013-03-15 | 2019-05-27 | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9682975B2 (el) |
| EP (2) | EP2970251B1 (el) |
| JP (2) | JP6543242B2 (el) |
| KR (1) | KR20150130386A (el) |
| CN (2) | CN105189491B (el) |
| AR (1) | AR095436A1 (el) |
| AU (2) | AU2014235132B2 (el) |
| BR (1) | BR112015020667A2 (el) |
| CA (2) | CA2906581C (el) |
| CY (1) | CY1121859T1 (el) |
| DK (1) | DK3514157T3 (el) |
| ES (1) | ES2727869T3 (el) |
| HK (1) | HK1220689A1 (el) |
| HU (2) | HUE064200T2 (el) |
| IL (2) | IL240617B (el) |
| MX (1) | MX365464B (el) |
| RU (1) | RU2015144035A (el) |
| SG (2) | SG10201706575UA (el) |
| TW (2) | TWI649317B (el) |
| UY (1) | UY35438A (el) |
| WO (1) | WO2014151291A1 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189491B (zh) | 2013-03-15 | 2018-07-06 | 建新公司 | 制备葡萄糖基神经酰胺合酶抑制剂的方法 |
| US10991982B2 (en) * | 2017-02-17 | 2021-04-27 | Westfälische Wilhelms-Universität Münster | Electrolyte-additive for lithium-ion battery systems |
| JP2021506920A (ja) | 2017-12-21 | 2021-02-22 | リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用 |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| US20230212123A1 (en) | 2020-04-28 | 2023-07-06 | The Regents Of The University Of Michigan | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same |
| JP2023534322A (ja) | 2020-07-24 | 2023-08-09 | ジェンザイム・コーポレーション | ベングルスタットを含む医薬組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB725226A (en) * | 1952-06-03 | 1955-03-02 | Berger Brothers Co | Improvements in or relating to an inflatable surgical pad |
| GB725228A (en) * | 1952-06-19 | 1955-03-02 | Roche Products Ltd | Substituted carbamic acid esters and process for the manufacture thereof |
| NL130759C (el) * | 1965-10-07 | |||
| DE4326510A1 (de) * | 1993-08-06 | 1995-02-09 | Bayer Ag | Verfahren zur Herstellung von Cyclohexen-Derivaten |
| WO1995021820A1 (fr) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| EP1811991B1 (en) | 2004-11-10 | 2018-11-07 | Genzyme Corporation | Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis |
| JP5285643B2 (ja) * | 2010-03-15 | 2013-09-11 | シャープ株式会社 | 半導体集積回路および電子情報機器 |
| TWI545124B (zh) * | 2010-11-12 | 2016-08-11 | 鹽野義製藥股份有限公司 | ６，７－不飽合－７－胺甲醯基嗎啡喃衍生物之結晶及其製造方法 |
| EP2685986B1 (en) * | 2011-03-18 | 2019-11-27 | Genzyme Corporation | Glucosylceramide synthase inhibitor |
| CN103702997A (zh) | 2011-06-22 | 2014-04-02 | 伊索凯姆公司 | 索非那新及其盐的制备方法 |
| JP2013053228A (ja) * | 2011-09-02 | 2013-03-21 | Asahi Kasei E-Materials Corp | エポキシ樹脂用硬化剤及びマイクロカプセル型エポキシ樹脂用硬化剤 |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| CN105189491B (zh) * | 2013-03-15 | 2018-07-06 | 建新公司 | 制备葡萄糖基神经酰胺合酶抑制剂的方法 |
-
2014
- 2014-03-13 CN CN201480026302.4A patent/CN105189491B/zh active Active
- 2014-03-13 SG SG10201706575UA patent/SG10201706575UA/en unknown
- 2014-03-13 JP JP2016501840A patent/JP6543242B2/ja active Active
- 2014-03-13 AR ARP140100982A patent/AR095436A1/es unknown
- 2014-03-13 US US14/776,443 patent/US9682975B2/en active Active
- 2014-03-13 WO PCT/US2014/025384 patent/WO2014151291A1/en active Application Filing
- 2014-03-13 RU RU2015144035A patent/RU2015144035A/ru not_active Application Discontinuation
- 2014-03-13 CA CA2906581A patent/CA2906581C/en active Active
- 2014-03-13 MX MX2015012842A patent/MX365464B/es active IP Right Grant
- 2014-03-13 EP EP14718835.3A patent/EP2970251B1/en active Active
- 2014-03-13 CN CN201810630738.4A patent/CN108658970A/zh active Pending
- 2014-03-13 TW TW103108899A patent/TWI649317B/zh not_active IP Right Cessation
- 2014-03-13 CA CA3092901A patent/CA3092901C/en active Active
- 2014-03-13 HU HUE19153389A patent/HUE064200T2/hu unknown
- 2014-03-13 DK DK19153389.2T patent/DK3514157T3/da active
- 2014-03-13 ES ES14718835T patent/ES2727869T3/es active Active
- 2014-03-13 EP EP19153389.2A patent/EP3514157B1/en active Active
- 2014-03-13 AU AU2014235132A patent/AU2014235132B2/en not_active Ceased
- 2014-03-13 SG SG11201506415XA patent/SG11201506415XA/en unknown
- 2014-03-13 TW TW107132577A patent/TW201900625A/zh unknown
- 2014-03-13 KR KR1020157027836A patent/KR20150130386A/ko not_active Application Discontinuation
- 2014-03-13 BR BR112015020667A patent/BR112015020667A2/pt not_active Application Discontinuation
- 2014-03-13 HU HUE14718835A patent/HUE043394T2/hu unknown
- 2014-03-14 UY UY0001035438A patent/UY35438A/es not_active Application Discontinuation
-
2015
- 2015-08-17 IL IL240617A patent/IL240617B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108676.6A patent/HK1220689A1/zh not_active IP Right Cessation
-
2017
- 2017-05-12 US US15/593,440 patent/US10065949B2/en active Active
-
2018
- 2018-06-03 IL IL259770A patent/IL259770B/en active IP Right Grant
- 2018-08-01 US US16/051,892 patent/US10604518B2/en active Active
-
2019
- 2019-01-18 AU AU2019200350A patent/AU2019200350A1/en not_active Abandoned
- 2019-05-27 CY CY20191100562T patent/CY1121859T1/el unknown
- 2019-06-13 JP JP2019109986A patent/JP6813626B2/ja active Active
-
2020
- 2020-02-14 US US16/791,854 patent/US10954230B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1123407T1 (el) | Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| EA201590554A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| CY1123581T1 (el) | Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων | |
| MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CL2015003731A1 (es) | Inhibidores de bromodominios | |
| MX366503B (es) | Derivados de amatoxina. | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| UY36075A (es) | Derivados de tubulisina | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| CY1122822T1 (el) | Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CY1118371T1 (el) | Αναστολεις του iap | |
| CY1123044T1 (el) | Νεες ενωσεις |